Welcome to our dedicated page for Vaxcyte news (Ticker: PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte stock.
Vaxcyte, Inc. (Nasdaq: PCVX) is a clinical-stage vaccine innovation company focused on broad-spectrum bacterial vaccines, and its news flow reflects progress across multiple pneumococcal conjugate vaccine programs and related manufacturing and regulatory milestones. Company announcements frequently highlight clinical trial updates for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate advancing to a Phase 3 adult program and being evaluated in a Phase 2 infant study, as well as VAX-24, a 24-valent PCV candidate in a Phase 2 infant study.
Investors and observers following PCVX news can expect detailed coverage of Phase 2 and Phase 3 study designs, topline safety, tolerability and immunogenicity data, and dose-selection decisions for both adult and pediatric indications. Recent releases have described the OPUS adult Phase 3 pivotal noninferiority trial for VAX-31, the multi-stage VAX-31 infant dose-finding study, and positive topline results from the VAX-24 infant Phase 2 trial, including IgG and opsonophagocytic assay responses compared with existing PCVs.
Vaxcyte’s news also covers regulatory interactions and designations, such as the U.S. Food and Drug Administration’s Breakthrough Therapy designation for VAX-31 in adults and its expansion to include prevention of pneumonia caused by Streptococcus pneumoniae. In addition, the company reports on manufacturing and supply-chain developments, including a dedicated manufacturing suite at Lonza and a long-term agreement with Thermo Fisher Scientific’s Patheon unit to provide fill-finish capacity in Greenville, North Carolina as part of its U.S. commercial supply strategy.
Other updates include business and financial results, capital allocation priorities, early-stage pipeline decisions involving candidates such as VAX-A1 and VAX-GI, and governance changes such as board and executive appointments. For readers tracking PCVX, this news page offers an ongoing view into Vaxcyte’s clinical progress, regulatory pathway, manufacturing readiness and corporate developments around its pneumococcal and broader bacterial vaccine pipeline.
Summary not available.
Vaxcyte, Inc. (Nasdaq: PCVX) successfully closed its public offering of 13,030,000 shares of common stock at a price of $41.00 each, along with pre-funded warrants for 1,000,000 shares at $40.999 per share. This offering raised approximately $575 million in gross proceeds before expenses. The underwriting team, including BofA Securities and Jefferies, fully exercised an option for an additional 1,830,000 shares. These funds will support Vaxcyte's mission in developing innovative vaccines for bacterial diseases, including its lead candidate, VAX-24, aimed at preventing invasive pneumococcal disease. Vaxcyte utilizes a unique cell-free protein synthesis platform to enhance vaccine production efficiency.
Vaxcyte, Inc. (Nasdaq: PCVX) has announced a public offering of 11,200,000 shares of common stock and pre-funded warrants for approximately $500 million in gross proceeds. The common stock is priced at $41.00 per share, while pre-funded warrants are priced at $40.999 each, with an exercise price of $0.001. The offering is set to close on April 21, 2023, subject to customary conditions. The underwriters have an option to purchase up to an additional 1,830,000 shares. This capital raise aims to support Vaxcyte's ongoing development of innovative vaccines, including its lead candidate, VAX-24, targeting invasive pneumococcal disease. Vaxcyte's technology leverages advanced synthetic techniques to enhance vaccine efficacy.
Vaxcyte, Inc. (Nasdaq: PCVX) has initiated an underwritten public offering of its common stock and pre-funded warrants, seeking to raise capital to support its innovative vaccine initiatives. The offering will include an option for underwriters to buy an additional 15% of shares. The financial details of the offering are not yet disclosed, and the completion will depend on market conditions. BofA Securities, Jefferies, SVB Securities, Evercore ISI, and Guggenheim Securities are the joint book-running managers for this offering. The company has a robust pipeline focusing on vaccines to combat bacterial diseases, including its lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine. This offering is designed to further strengthen Vaxcyte’s position in the vaccine market.
Vaxcyte, Inc. (PCVX) announced positive results from the VAX-24 Phase 2 study in adults aged 65 and older, confirming robust opsonophagocytic activity (OPA) immune responses across all 24 serotypes. The VAX-24 2.2mcg dose met non-inferiority criteria for 18 of 20 serotypes common with Prevnar 20 and demonstrated superior responses for four additional serotypes. Six-month safety data indicated similar safety and tolerability results compared to Prevnar 20. Vaxcyte plans to advance VAX-24 to a Phase 3 study, with topline data expected in 2025. The data supports VAX-24's potential as a best-in-class pneumococcal conjugate vaccine (PCV), aiming to reduce the incidence of invasive pneumococcal disease (IPD) among adults.
Vaxcyte, Inc. (Nasdaq: PCVX) will host a webcast and conference call on April 17, 2023, at 7:30 a.m. ET to discuss results from its Phase 2 study of VAX-24, a 24-valent pneumococcal conjugate vaccine candidate, targeting adults aged 65 and older. The discussion will include detailed six-month safety data from adult Phase 2 studies. VAX-24 aims to provide broad-spectrum protection against invasive pneumococcal diseases. Vaxcyte is utilizing modern synthetic techniques like the XpressCF™ cell-free protein synthesis platform to create high-fidelity vaccines efficiently. The company's pipeline also features candidates such as VAX-31, VAX-A1, VAX-PG, and VAX-GI, addressing various bacterial infections.
Vaxcyte, Inc. (Nasdaq: PCVX) has initiated a Phase 2 clinical study of its lead vaccine candidate, VAX-24, in healthy infants. This broad-spectrum 24-valent pneumococcal conjugate vaccine aims to prevent invasive pneumococcal disease (IPD). The study will assess safety, tolerability, and immunogenicity compared to the current standard, PCV15. The first stage involves 48 infants, while the second stage will expand to approximately 750 infants. Vaxcyte expects to share topline results by 2025, highlighting VAX-24’s potential to enhance coverage against 20-25% more strains of IPD than existing vaccines.
Vaxcyte, Inc. (Nasdaq: PCVX) has received FDA clearance for its VAX-24 IND application aimed at preventing invasive pneumococcal disease (IPD) in infants, with a Phase 2 study expected to start in Q2 2023. The company also reported positive topline results from the Phase 1/2 study of VAX-24 in adults 18-64, showing its potential as a best-in-class vaccine. In 2022, Vaxcyte raised approximately $805 million through equity offerings, strengthening its financial position with cash reserves of $957.9 million as of December 31, 2022. The company anticipates significant milestones in 2023, including the submission of a new IND application for VAX-31.
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, has received FDA clearance for its infant IND application for VAX-24, a 24-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease (IPD). The Phase 2 infant study is set to begin in Q2 2023, with topline safety and immunogenicity results expected by 2025. The vaccine aims to address significant health concerns related to IPD, particularly in infants and young children. The Phase 2 study will evaluate safety and efficacy across different dosage levels, compared to existing vaccines, targeting improved immune responses and broader coverage.
Vaxcyte, Inc. (Nasdaq: PCVX) will report its financial results for Q4 and full year 2022 on February 27, 2023, post-market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide a business update. Vaxcyte partners with advanced synthetic techniques to develop high-fidelity vaccines targeting bacterial diseases. Their lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease. Their pipeline includes other vaccine candidates aimed at various bacterial infections, enhancing their commitment to addressing significant health concerns.